Australia's Orthocell jumps on surgical adoption of nerve repair device

Orthocell

16/09/2025 03:25

** Orthocell OCC.AX jumps as much as 10.9% to A$1.22, highest since August 29

** Stock posts biggest intraday pct gain since June 26

** Regenerative medicine developer says its flagship nerve repair device, Remplir, introduced to urologists in Australia for use in nerve-sparing robotic-assisted radical prostatectomy

** Adds Remplir so far used in 40 such surgical cases

** Around 1 mln shares traded, 2.4x the 30-day avg

** OCC last up 9.1%, trimming YTD losses to 11.4%

 (Reporting by Shruti Agarwal in Bengaluru)

 ((Shruti.Agarwal@thomsonreuters.com))